Author

A. Rashidfarrokhi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Herrera· 3 shared A. Tsirigos· 3 shared C. M. Rudin· 3 shared K. M. Khanna· 3 shared K.-K. Wong· 3 shared R. Pillai· 3 shared S. B. Koralov· 3 shared T. Papagiannakopoulos· 3 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Herrera

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growth

A. Rashidfarrokhi, R. Pillai, Y. Hao, W. Wu, B. Karadal-Ferrena, S. G. dimitriadoy, M. Cross, A. H. Yeaton, S. Ming Huang, A. J. Bhutkar, A. Herrera, S. Rajalingam, M. Hayashi, K.-l. Huang, E. Bartnicki, , T. Papagiannakopoulos

This study identifies a LKB1-LIF signaling axis in tumors that promotes immune evasion by reprogramming myeloid cells, and shows that inhibiting LIF signaling reduces tumor growth.

bioRxiv · Jul 15, 2023 · PreprintCancer Biology

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

R. Pillai, S. E. LeBoeuf, Y. Hao, C. New, J. Blum, A. Rashidfarrokhi, S. M. Huang, C. Bahamon, W. L. Wu, B. Karadal-Ferrena, A. Herrera, E. Ivanova, M. Cross, J. P. Bossowski, H. Ding, , T. Papagiannakopoulos

This study shows that DRP-104, a glutamine antagonist, suppresses KEAP1 mutant lung tumor growth and enhances response to checkpoint blockade by inhibiting glutamine metabolism and improving T cell function.

bioRxiv · Jun 27, 2023 · PreprintCancer Biology

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

A. M. Zavitsanou, Y. Hao, W. L. Wu, E. Bartnicki, R. Pillai, T. Karakousi, A. Herrera, A. Karatza, A. Rashidfarrokhi, S. Solis, M. Ciampricotti, A. H. Yeaton, E. Ivanova, C. A. Wohlhieter, T. B. Buus, , S. B. Koralov

This study shows KEAP1 mutations in lung adenocarcinoma lead to immune evasion by reducing dendritic cell and T cell responses, contributing to immunotherapy resistance.

bioRxiv · Sep 24, 2021 · PreprintCancer Biology

Sphingomyelin biosynthesis is essential for phagocytic signaling during Mycobacterium tuberculosis host cell entry

P. Niekamp, G. Guzman, H. Leier, A. Rashidfarrokhi, V. Richina, F. Pott, J. Holthuis, F. G. Tafesse

bioRxiv · Jul 12, 2019 · PreprintMicrobiology